Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Stroke. 2020 Mar 11;51(4):1128–1134. doi: 10.1161/STROKEAHA.119.028515

Figure 2.

Figure 2.

(a) Median sST2 sampled < 5 days from initial hemorrhage in patients developing new/worsening EAs was higher than in patients who did not develop new/worsening EAs (p = 0.024). There was no difference in median sST2 levels between patients who developed new background deterioration compared to those who did not. (b) IL-6 and (c) CRP were not significantly associated with new EAs or new background deterioration.